W Schwartzkopff
About
In The Last Decade
W Schwartzkopff
48 papers receiving 298 citations
Peers
Comparison fields: 5 of 78
- Molecular Biology 119
- Surgery 85
- Endocrinology, Diabetes and Metabolism 74
- Epidemiology 42
- Plant Science 38
Countries citing papers authored by W Schwartzkopff
This map shows the geographic impact of W Schwartzkopff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W Schwartzkopff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W Schwartzkopff more than expected).
Fields of papers citing papers by W Schwartzkopff
This network shows the impact of papers produced by W Schwartzkopff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W Schwartzkopff. The network helps show where W Schwartzkopff may publish in the future.
Co-authorship network of co-authors of W Schwartzkopff
This figure shows the co-authorship network connecting the top 25 collaborators of W Schwartzkopff. A scholar is included among the top collaborators of W Schwartzkopff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W Schwartzkopff. W Schwartzkopff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | Effective therapeutic measures for reducing lipoprotein (A) in patients with dyslipidemia: Lipoprotein (A) reduction with sustained-release bezafibrate | 27 |
| 3 | 24 | |
| 4 | [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia]. | 2 |
| 5 | 1 | |
| 6 | 1 | |
| 7 | [Changes in serum lipid fractions as a side effect of oral retinoids]. | 4 |
| 8 | 3 | |
| 9 | [Changes in beta acetyldigoxin resorption following administration of beta-sitosterine or cholestyramine]. | 2 |
| 10 | [Comparative studies on the reduction of lipids using clofibric acid and clofibrate in hyperlipoproteinemias]. | 1 |
| 11 | 1 | |
| 12 | 1 | |
| 13 | [Clinical and experimental studies on a gelatin plasma expander with special reference to renal hemodynamics in normovolemic and hypovolemic subjects]. | 1 |
| 14 | 3 | |
| 15 | 3 | |
| 16 | 3 | |
| 17 | 4 | |
| 18 | 7 | |
| 19 | 2 | |
| 20 | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.